Cargando…

Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution

BACKGROUND: Breast cancer is the most common malignancy among women worldwide. Previous studies have shown factors influencing breast cancer patients' survival, including histopathological grading, stage, histopathological type, hormone receptors, and the number of mitotic images. This study ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Prihantono, Faruk, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428064/
https://www.ncbi.nlm.nih.gov/pubmed/37592933
http://dx.doi.org/10.1016/j.sopen.2023.07.016
_version_ 1785090383403810816
author Prihantono
Faruk, Muhammad
author_facet Prihantono
Faruk, Muhammad
author_sort Prihantono
collection PubMed
description BACKGROUND: Breast cancer is the most common malignancy among women worldwide. Previous studies have shown factors influencing breast cancer patients' survival, including histopathological grading, stage, histopathological type, hormone receptors, and the number of mitotic images. This study aimed to determine the survival rate in breast cancer patients based on neoadjuvant chemotherapy (NAC) response and regimen. METHODS: This was an observational analytic study with a retrospective design. The population was breast cancer patients at our institution who had undergone NAC. Kaplan–Meier analysis using the log-rank method was used to determine the level of survivability (overall survival [OS] and disease-free survival [DFS]) of patients based on chemotherapy response and regimen. RESULTS: The NAC overall response rate of breast cancer patients was 93.17 %, whereas the non-response rate was 6.83 %. Significant differences existed in the DFS of patients by chemotherapy response (p = 0.010). Patients with a complete response had a mean survival of 71.37 ± 2.92 months, those with progressive disease had a mean survival of 64.80 ± 15.58 months, and overall patients had a mean survival of 68.56 ± 10.452 months. Patients with a complete response had a mean recurrence time of 69.54 ± 7.48 months; this was 57.53 ± 19.06 months in those with progressive disease, for an overall time of 65.41 ± 13.81 months. No significant difference existed between the NAC regimens in OS and DFS (p = 0.901 and p = 0.798, respectively). CONCLUSION: Generally, the response to NAC in breast cancer was very good. The DFS rates were significantly different from the chemotherapy response but not from the NAC regimen.
format Online
Article
Text
id pubmed-10428064
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104280642023-08-17 Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution Prihantono Faruk, Muhammad Surg Open Sci Research Paper BACKGROUND: Breast cancer is the most common malignancy among women worldwide. Previous studies have shown factors influencing breast cancer patients' survival, including histopathological grading, stage, histopathological type, hormone receptors, and the number of mitotic images. This study aimed to determine the survival rate in breast cancer patients based on neoadjuvant chemotherapy (NAC) response and regimen. METHODS: This was an observational analytic study with a retrospective design. The population was breast cancer patients at our institution who had undergone NAC. Kaplan–Meier analysis using the log-rank method was used to determine the level of survivability (overall survival [OS] and disease-free survival [DFS]) of patients based on chemotherapy response and regimen. RESULTS: The NAC overall response rate of breast cancer patients was 93.17 %, whereas the non-response rate was 6.83 %. Significant differences existed in the DFS of patients by chemotherapy response (p = 0.010). Patients with a complete response had a mean survival of 71.37 ± 2.92 months, those with progressive disease had a mean survival of 64.80 ± 15.58 months, and overall patients had a mean survival of 68.56 ± 10.452 months. Patients with a complete response had a mean recurrence time of 69.54 ± 7.48 months; this was 57.53 ± 19.06 months in those with progressive disease, for an overall time of 65.41 ± 13.81 months. No significant difference existed between the NAC regimens in OS and DFS (p = 0.901 and p = 0.798, respectively). CONCLUSION: Generally, the response to NAC in breast cancer was very good. The DFS rates were significantly different from the chemotherapy response but not from the NAC regimen. Elsevier 2023-07-27 /pmc/articles/PMC10428064/ /pubmed/37592933 http://dx.doi.org/10.1016/j.sopen.2023.07.016 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Prihantono
Faruk, Muhammad
Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
title Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
title_full Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
title_fullStr Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
title_full_unstemmed Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
title_short Neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
title_sort neoadjuvant chemotherapy response, disease-free survival, and overall survival of breast cancer in a single institution
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428064/
https://www.ncbi.nlm.nih.gov/pubmed/37592933
http://dx.doi.org/10.1016/j.sopen.2023.07.016
work_keys_str_mv AT prihantono neoadjuvantchemotherapyresponsediseasefreesurvivalandoverallsurvivalofbreastcancerinasingleinstitution
AT farukmuhammad neoadjuvantchemotherapyresponsediseasefreesurvivalandoverallsurvivalofbreastcancerinasingleinstitution